Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Status:
Completed
Trial end date:
2020-02-29
Target enrollment:
Participant gender:
Summary
This was a multicenter, randomized, double-blind, phase III trial. This clinical study
evaluates the efficacy and safety of Apatinib in patients with advanced liver cancer who have
progressed on Systemic Therapy (Chemotherapy and/or Targeted Therapy).
Approximately 400 patients who meet the entry criteria will be randomly assigned in a 2:1
ratio to Apatinib or placebo (1/3 chance to receive placebo).
Primary endpoint of the study is overall survival.